PMCPA Case Library

1,752 PMCPA Rulings.
Every One Analysed.

The only structured, searchable PMCPA case library in the UK. Expert video walkthroughs, podcast episodes, and MCQ assessments on every ruling — so you understand why companies breach the Code, not just that they did.

▶ Video analysis per case
🎧 Podcast per case
✍ MCQ + CPD certificate
🔒 From £299/year
1752+
Case Studies
5 min
Per Video
5 pts
Per Case Passed
8
Themes
📚
Subscribe for full case library access
Read free summaries below, or subscribe to unlock expert video walkthroughs, podcast audio and CPD certificates.
Sign in See plans ↓
Free — Browsing
✓ Browse all 1752+ case titles
✓ Filter by theme & therapy area
✓ See case reference, company & outcome
✗ Search by company or clause
✗ Video walkthroughs
✗ Podcast episodes
✗ MCQ assessments & CPD certificates
Subscribed — Full Access
✓ Search by company, clause & case ref
✓ Expert video walkthrough per case
✓ Podcast episode per case
✓ MCQ quiz — 5 CPD points per pass
✓ Personalised CPD completion certificate
✓ New cases added monthly
Subscribe from £299/year →
Search by company, clause, case reference... 🔒
All (1752) Social Media & Digital (720) HCP Hospitality & Meetings (431) Data & Publications (321) Off-label Promotion (219) Patient Organisations (44) Transfers of Value (9) Promotional Material (4) Samples & Gifts (2)
Therapy Area: All areas Other (360) Oncology (218) Cardiovascular (189) Respiratory (178) CNS & Neurology (169) Infectious Diseases (115) Diabetes (114) Rare Diseases (104) Immunology & Rheumatology (84) Dermatology (67) Obesity & Weight Management (63) Musculoskeletal & Bone (60) Ophthalmology (31)
Showing 54 results · Social Media & Digital · Rare Diseases  · Clear
🔒 Subscribers only
AUTH/3926/6/24
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Pfizer
Two LinkedIn posts (one by a UK health authority, one by its employee) discussed NICE final draft guidance and named Pfizer’s medicine voxelotor, linking to a health authority website article.The…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3909/5/24
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
GSK Omjjara (momelotinib) HCP website
An anonymous, contactable complainant (described as a health professional) alleged a GSK promotional webpage for Omjjara (momelotinib) had not been certified for mobile phone use.The complainant sa…
Clauses: NONE
2024 🔒 Subscribe
🔒 Subscribers only
AUTH/3745/2/23
Social Media & Digital Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Tetris Pharma
A named complainant (not a health professional) received a LinkedIn sponsored message (Feb 2022) promoting Ogluo (glucagon), a prescription only medicine.The message introduced Ogluo, described pro…
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3743/2/23
Social Media & Digital Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
BioMarin
An anonymous (initially contactable) complainant alleged a senior BioMarin leader based in the United Arab Emirates posted on LinkedIn referencing “recent approvals by FDA” and “EMA approval�…
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3794/7/23
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Merck Serono fertility event
An anonymous, non-contactable complainant (describing themselves as a fertility specialist) complained about a Merck Serono fertility educational meeting in London attended by ~60 HCPs.The complain…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3765/4/23
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Takeda Rare Disease Hub website
An anonymous, contactable UK health professional complained about Takeda’s “Rare Disease Hub” website (certified as promotional and gated for UK HCPs via attestation).Concerns included: a bla…
Clauses: NONE
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3751/3/23
Social Media & Digital Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Otsuka
An ex-employee complained about the Jinarc (tolvaptan) UK training portal wording, saying it implied HCPs must register details to be eligible to prescribe, while also stating enrolment was “not …
Clauses: 9.1,7.2
2023 🔒 Subscribe
🔒 Subscribers only
AUTH/3676/7/22
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Roche
A whistleblowing complainant raised concerns about Roche’s internal compliance procedures and a patient organisation website that had been supported by a grant (grant dated November 2020).The com…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3623/3/22
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Aimmune
A former employee complained about a post on the Aimmune Therapeutics US LinkedIn account about presenting abstracts at WSAAI, referring to an OIT treatment for peanut allergy and naming “Peanut …
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3696/10/22
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
SOBI
An anonymous, non-contactable complainant challenged a corporate article sponsored by SOBI (Swedish Orphan Biovitrum Ltd) and published in print and online by The Guardian.The complainant alleged t…
Clauses: NONE
2022 🔒 Subscribe
🔒 Subscribers only
AUTH/3473/2/21
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Alnylam
A contactable complainant alleged a LinkedIn post by an agency promoted Oxlumo (lumasiran) to the public, naming the product and describing it as the “first and only FDA-approved prescription med…
Clauses: NONE
2021 🔒 Subscribe
🔒 Subscribers only
AUTH/3465/2/21
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Vifor
An anonymous, contactable complainant (a concerned UK health professional) alleged Vifor Pharma UK Limited used the PIVOTAL study to promote off-licence use of Venofer (iron sucrose IV).The complai…
Clauses: NONE
2021 🔒 Subscribe
🔒 Subscribers only
AUTH/3475/2/21
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Lundbeck
An anonymous, contactable complainant (health professional) raised concerns about alleged promotion of Vyepti (eptinezumab), which did not have a UK marketing authorisation at the time.The complain…
Clauses: NONE
2021 🔒 Subscribe
🔒 Subscribers only
AUTH/3407/10/20
Social Media & Digital Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Pharmasure breached undertaking by leaving Meriofert superiority-style claims on UK website
Ferring alleged Pharmasure breached an undertaking given in Case AUTH/3227/7/19 by continuing to display promotional claims for Meriofert (menotrophin) on its UK website.Ferring monitored the websi…
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3345/5/20
Social Media & Digital Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Sobi breached ABPI Code over ‘No anaphylaxis or allergic reactions’ claim in Alprolix BMJ hosted adv
A UK health professional complained about a Sobi advertisement for Alprolix (eftrenonacog alfa) on a BMJ-hosted webpage.The section was presented under a tolerability heading referencing clinical s…
Clauses: 3.2,9.1
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3354/5/20
Social Media & Digital Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Takeda breached Clause 7.11 by calling Takhzyro “new” more than 12 months after promotion began
A health professional complained about a BMJ-hosted promotional webpage/banner journey for Takhzyro (lanadelumab) stating: “Introducing Takhzyro: a new preventative treatment for use in type I/II…
Clauses: 7.2,7.3,7.4
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3356/5/20
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Alexion
A UK health professional complained about a PNH guidance document on a named hospital website (dated Oct 2014; ref UK/SPNH/12/0022(3)a).The document appeared educational and stated it was supported…
Clauses: NONE
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3370/8/20
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Ferring
A UK health professional complained that a Ferring-commissioned/sponsored supplement (“Trends Urology and Men’s Health”) was still available online despite stating it would be hosted only unt…
Clauses: NONE
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3369/8/20
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Pfizer
A UK health professional complained about two Ecalta (anidulafungin) leavepieces (refs ECA359 and PP-ERA-GBR-0169) found online via Google search results and direct links referencing the Pfizerpro …
Clauses: NONE
2020 🔒 Subscribe
🔒 Subscribers only
AUTH/3274/10/19
Social Media & Digital Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Diurnal
A “concerned UK health professional” complained about a Diurnal corporate website page in the health professionals section.The page combined “Products and Pipeline” content and included a t…
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3217/6/19
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Otsuka
A health professional complained that Otsuka’s Jinarc (tolvaptan) training website for UK health professionals was promotional but did not meet Code requirements for promotional material.The comp…
Clauses: NONE
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3231/7/19
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Shield and Norgine
A UK health professional complained about content on the Feraccru (ferric maltol) website (Feraccru used to treat adults with iron deficiency).The website stated “Feraccru is well tolerated”, w…
Clauses: NONE
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3184/4/19
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
GW Pharmaceuticals website
A “concerned UK health professional” complained about GW Pharmaceuticals’ UK corporate website (gwpharm.co.uk).GW was the marketing authorisation holder (MAH) of Sativex; in the UK, Sativex w…
Clauses: NONE
2019 🔒 Subscribe
🔒 Subscribers only
AUTH/3163/2/19
Social Media & Digital Not Upheld 🏥 Rare Diseases ▶ Video 🎙 Podcast
Alexion
A UK health professional complained about a LinkedIn post seen in their feed, originally raised in an earlier case (AUTH/3051/6/18).The post (from Alexion’s US parent account) stated Alexion had …
Clauses: NONE
2019 🔒 Subscribe
1 2 3 Next → Page 1 of 3 — 54 cases
Unlock the Full Case Library
Annual subscription — instant access, cancel anytime.
🏆
The only PMCPA case library of its kind
No other provider publishes a structured, searchable library of PMCPA rulings with video and podcast. A single half-day compliance workshop from a specialist provider typically costs £499+ — for one session. Individual access here is £299 for a full year of 2,000+ cases.
PMCPA Case Library — Team (100 seats)
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
Enquire for bulk pricing →
Individual
For a single learner
£299
per year
Less than a single half-day workshop
  • 1 user seat
  • All 1752+ case studies
  • Video + podcast per case
  • MCQ quiz per case
  • 5 points per case passed
  • New cases added monthly
Create account or sign in to buy
Most Popular
Team 5
Up to 5 team members
£999
per year (£200/seat)
£200/person — the most cost-effective team option
  • 5 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • New cases added monthly
  • Admin management portal
Create account or sign in to buy
Team 25+
25+ team members
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
  • 25 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • Bulk seat management
  • Priority support
Enquire for bulk pricing →

Questions? Email [email protected]  ·  14-day money-back guarantee  ·  Annual subscription, auto-renews